p53 regulation Teamwork between RING domains of Mdm2 and MdmX

被引:40
|
作者
Wang, Xinjiang [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
关键词
p53; Mdm2; MdmX; Mdm2/MdmX; MDM4; RING domains; protein stability; ubiquitination; lethality; knockout; knockin; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; UBIQUITIN LIGASE; EMBRYONIC LETHALITY; IN-VIVO; ANTAGONISTIC PLEIOTROPY; MDM2-DEFICIENT MICE; CELL SENESCENCE; QUIESCENT CELLS; ACTIVATES P53;
D O I
10.4161/cc.10.24.18662
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
p53 is a major tumor suppressor frequently inactivated through direct gene mutation and alternative mechanisms including overexpression of Mdm2 and MdmX. Both Mdm2 and MdmX are essential for negative regulation of p53 in vivo in a mutually dependent manner. The RING domain dependent E3 ligase activity of Mdm2 has been shown to be essential for negative regulation of p53. The prevailing model has dubbed MdmX as an inhibitor of p53 transcriptional activity through direct binding of its N-terminal domain to p53. However, recent findings established an essential role of the RING domain of MdmX in p53 degradation in vitro and in vivo. Biochemically, Mdm2 on its own is a monoubiquitination E3 ligase, however, MdmX can convert Mdm2 into a polyubiquitination E3 ligase necessary for p53 proteasomal degradation in cells, through their RING-RING interaction. While Mdm2 is the catalytic component of Mdm2/MdmX E3 complex, MdmX is both the activating component and a substrate of the holoenzyme. Knock-in of RING mutant MdmX in mice causes p53-dependent embryonic lethality in a similar manner as knockout of MdmX whole gene. These recent advancements in the field assigned an essential role of the RING domain of MdmX in negative regulation of p53 in vivo, just like Mdm2 RING domain, through p53 degradation.
引用
收藏
页码:4225 / 4229
页数:5
相关论文
共 50 条
  • [21] MDM2 interacts with MDMX through their RING finger domains
    Tanimura, S
    Ohtsuka, S
    Mitsui, K
    Shirouzu, K
    Yoshimura, A
    Ohtsubo, M
    FEBS LETTERS, 1999, 447 (01) : 5 - 9
  • [22] Parallel discovery of multiple chemotypes antagonizing p53/mdm2/mdmx
    Alexander, Doemling
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3422S - 3422S
  • [23] Structural Adaptation of Secondary p53 Binding Sites on MDM2 and MDMX
    Higbee, Pirada Serena
    Dayhoff II, Guy W.
    Anbanandam, Asokan
    Varma, Sameer
    Daughdrill, Gary
    JOURNAL OF MOLECULAR BIOLOGY, 2024, 436 (13)
  • [24] Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2
    Ohtsubo, Chihiro
    Shiokawa, Daisuke
    Kodama, Masami
    Gaiddon, Christian
    Nakagama, Hitoshi
    Jochemsen, Aart G.
    Taya, Yoichi
    Okamoto, Koji
    CANCER SCIENCE, 2009, 100 (07): : 1291 - 1299
  • [25] The p53/MDM2/MDMX-targeted therapies—a clinical synopsis
    Liren Jiang
    Joanna Zawacka-Pankau
    Cell Death & Disease, 11
  • [26] On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins
    ElSawy, Karim M.
    Verma, Chandra S.
    Joseph, Thomas L.
    Lane, David P.
    Twarock, Reidun
    Caves, Leo S. D.
    CELL CYCLE, 2013, 12 (03) : 394 - 404
  • [27] Differential binding of p53 and nutlin to MDM2 and MDMX Computational studies
    Joseph, Thomas Leonard
    Madhumalar, Arumugam
    Brown, Christopher John
    Lane, David P.
    Verma, Chandra
    CELL CYCLE, 2010, 9 (06) : 1167 - 1181
  • [28] DISRUPTION OF P53/MDM2/MDMX PROTEIN-PROTEIN INTERACTIONS
    Topper, M.
    Zhou, M.
    Anderson, L.
    McLaughlin, M.
    BIOPOLYMERS, 2009, 92 (04) : 332 - 332
  • [29] MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin
    Hu, Baoli
    Gilkes, Daniele M.
    Farooqi, Bilal
    Sebti, Said M.
    Chen, Jiandong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (44) : 33030 - 33035
  • [30] Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms
    Stad, R
    Little, NA
    Xirodimas, DP
    Frenk, R
    van der Eb, AJ
    Lane, DP
    Saville, MK
    Jochemsen, AG
    EMBO REPORTS, 2001, 2 (11) : 1029 - 1034